Validation and Clinical Implementation of Breast IHC AI
Learn how Kaiser Permanente deployed Breast IHC AI as a laboratory developed test.
Validation and Clinical Implementation of Breast IHC AI Read More »
ER
Breast IHC AI Brochure
Learn how this AI-powered tool standardized breast cancer biomarker quantification to include HER2 low and ultralow.
Breast IHC AI Brochure Read More »
Development & Validation of an AI-based Workflow for Clinical Scoring of HER2, ER, PR, & Ki67 Immunohistochemistry in Breast Cancer Tissue
Explore Breast IHC AI, a deep learning-based workflow for evaluation of breast cancer.
Low and Ultralow HER2 Expression in Breast Cancer is Now Detectable by Indica Labs’ Breast IHC AI
Albuquerque, NM, April 30, 2025 – Indica Labs, the leading provider of AI-powered digital pathology solutions, announces today an update to their Breast IHC AI suite, an image analysis tool used for the quantification of HER2, ER, PR, and Ki67 within AI-identified, tumor regions, of breast cancer tissue specimens. The HER2 algorithm will now include functionality for the detection of low and ultralow HER2 expression in breast cancer.